An Exploratory Patient Centric Analysis of the ELECT Trial: A Phase 3 Study of Efficacy and Safety of Lanreotide Autogel/Depot (LAN) Treatment for Patients (pts) with Carcinoid Syndrome (CS) Abstract #1684

Introduction: In ELECT, LAN 120mg every 4 weeks significantly reduced octreotide rescue therapy use for symptomatic CS control vs placebo (PBO).
Aim(s): This patient centric analysis explores the treatment effect on patient benefit during this trial.
Materials and methods: The analysis used all patient-reported outcomes collected during the double-blind phase of ELECT: daily diarrhea and flushing symptoms, octreotide rescue use and EORTC QLQ-C30 and QLQ-GINET.21 questionnaires at baseline and week 12. We applied principal component (PC) analysis on the baseline data to identify independent variable clusters, identified summary measures that were highly correlated to these PCs, derived minimum clinical important differences (MCID) and performed a responder analysis.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: George Camba
Keywords: SSA, carcinoid, symptoms

To read results and conclusion, please login ...

Further abstracts you may be interested in

#943 SSA Therapy for Patients with Bronchial Carcinoids (BC) in the Community Setting
Introduction: SSA show antitumoral effect in GEP-NETs in 2 phase III trials, PROMID and CLARINET. However, patients (pts) with BC were not included in these studies.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD Carlos Lopez Lopez
Keywords: bronchial, carcinoid, SSA
#1925 SSA-, H1, H2- and Leukotriene Receptor Blockade Eliminates Handicapping Symptoms from Atypical Carcinoid Syndrome
Introduction: The patient is a female, 59 yrs , previously healthy except from mild allergic rinitis since 12 years of age and at 49 a suspected anaphylaxis after hazelnut intake.
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: MD PhD Kristina Linder Ekberg
Keywords: PGD2
#1812 Correlation of Plasma (p) and Urine (u) 5-HIAA Levels in Patients (pts) with Carcinoid Syndrome (CS) – Post-Hoc Analyses from the TELESTAR Study
Introduction: Telotristat ethyl (TE) is an oral tryptophan hydroxylase inhibitor in development for treating CS symptoms. During the double-blind treatment [DBT] period of the phase 3, 12-week, placebo-controlled TELESTAR study, TE was well tolerated and significantly reduced bowel-movement frequency and u5-HIAA levels compared with placebo (PBO) in NET patients with CS treated with a SSA.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Others
Presenting Author: Marianne Pavel
#188 Carcinoid
Introduction: There is a serious need to develop a clear framework based on multidisciplinary team practice, in order to facilitate early detection and management of carcinoid.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Assistant Prof Maria Derylo
Authors: Derylo M, Daly B, Duffy E, Rita M, ...
#303 Pancreatic Metastases from Bronchopulmonary Atypical Carcinoid: An Uncommon Tumor Spreading to a Rare Location
Introduction: We report an uncommon case of pancreatic metastases from a bronchial atypical carcinoid.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Prof Laura De Marinis
Close
Notice
Important Notice:

In preparation of the upcoming ENETS Barcelona 2018 Annual Conference, we have discovered in the world wide web at least one professional entity suggestive of possessing an ENETS mandate for conference registrations. Therefore, we must inform you that 100% of all conference participants are registered through ENETS official website www.enets.org and http://enetsconference.org/. There are no further options to validly register for Barcelona 2018 (or for any other ENETS event).

Please stay away from fraudulent scams abusing the ENETS acronym to register – and charge you above official ENETS conference fees! Such entities, against whom ENETS presses criminal charges, are neither authorized, nor commissioned nor instructed by ENETS to make such representations.